SLXN Earnings Silexion Therapeutics Corp
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Net income
ROE
Reported EPS history
1–15 of 15
| Q2 2026 | 2026-06-30 | 5.17 | 2026-08-14 | 10-Q |
| Q1 2026 | 2026-03-31 | 8.50 | 2026-05-15 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | -20.79 | 2026-03-17 | 10-K |
| FY 2025 | 2025-12-31 | 89.60 | 2026-03-17 | 10-K |
| Q3 2025 | 2025-09-30 | 28.80 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | 43.19 | 2025-08-12 | 10-Q |
| Q1 2025 | 2025-03-31 | 38.40 | 2025-05-13 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | -2614.60 | 2025-03-18 | 10-K |
| FY 2024 | 2024-12-31 | 3949.40 | 2025-03-18 | 10-K |
| Q3 2024 | 2024-09-30 | 2742.50 | 2024-11-14 | 10-Q |
| Q2 2024 | 2024-06-30 | 1978.00 | 2024-08-29 | 10-Q |
| Q1 2024 | 2024-03-31 | 1843.50 | — | — |
| FY 2023 | 2023-12-31 | 6634.50 | — | — |
| Q3 2023 | 2023-09-30 | 1053.00 | — | — |
| Q2 2023 | 2023-06-30 | 8829.00 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.